Certara, Inc.
CERT US
CERT USCertara, Inc.
United States Composite13.63
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. William F. Feehery Ph.D.
- Full Time Employees
- 1,150
- Sector
- Healthcare
- Industry
- Health Information Services
- Address
- 100 Overlook Center Princeton NJ United States 08540
- IPO Date
- Dec 11, 2020
- Website
- www.certara.com
- Business
- Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, the Netherlands, the Philippines, Poland, Portugal, Spain, Switzerland, and the United Kingdom. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Company News
Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
Barclays Remains a Hold on Certara (CERT)
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software
Certara to Participate in the Jefferies Global Healthcare Conference
Certara to Participate in the Jefferies Global Healthcare Conference
Certara Appoints New Chief Human Resources Officer & General Counsel
Certara Appoints New Chief Human Resources Officer & General Counsel
Certara, Inc. (NASDAQ:CERT) Q1 2024 Earnings Call Transcript
Certara First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Q1 2024 Certara Inc Earnings Call
Certara Inc (CERT) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and ...
Certara Inc (CERT) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and Capitalizing on Software Growth
Certara (CERT) Gets a Hold from JMP Securities
Q1 2024 Certara Inc Earnings Call Transcript
Certara, Inc. (CERT) Q1 Earnings Meet Estimates
Certara Non-GAAP EPS of $0.10 in-line, revenue of $96.7M beats by $3.07M
Certara Inc (CERT) Q1 2024 Earnings: Mixed Results Amidst Revenue Growth and Net Loss
Certara Inc (CERT) Q1 2024 Earnings: Mixed Results Amidst Revenue Growth and Net Loss